United Therapeutics (UTHR +0.1%) says it's received approval to perform a human Phase I study in...

United Therapeutics (UTHR +0.1%) says it's received approval to perform a human Phase I study in Australia using Pluristem Therapeutics' (PSTI +1.6%) PLacental eXpanded cells in patients diagnosed with Pulmonary Arterial Hypertension. United Therapeutics and Pluristem entered into a licensing agreement in 2011 that allows UTHR to develop, market and sell PSTI's PLX-PAD cells.

From other sites
Comments (1)
  • thekrohn
    , contributor
    Comment (1) | Send Message
    Became interested in medical tech several years ago when I develoved a prostate problem and was told I needed a turp, Did a little research and learned that with the "Green Light' procedure just becoming available I or practically nobody needed a turp. Now both my wife and myself are both potential candidates for the new bio-tech approach to age reated ailments such as we both endure. Although we may not live long enough to see them come to market we can but hope. Based on my experience I would caution all potential patients to ask qustions and not accept a doctors's opionion until you have done some research or risk having an unnecessary turp, or amputation (the latter performed in many cases for blood circulation problems) when neither in all probability may no longer be necessary,
    11 Apr 2013, 03:33 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs